Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Eledon Pharmaceuticals Inc.
Headquarters: Irvine, CA, United States of America
Website: https://eledon.com/
Year Founded: 2004
Status: Public
Industry Sector: HealthTechnology
CEO: David-Alexandre C. Gros, MD, MBA
Number Of Employees: 31
Enterprise Value: $60,776,402
PE Ratio: -1.03
Exchange/Ticker 1: NASDAQ:ELDN
Exchange/Ticker 2: N/A
Latest Market Cap: $180,244,208
BioCentury | Nov 1, 2024
Finance
How Fairmount’s Paragon incubator steered two more companies to NASDAQ
In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M
BioCentury | Oct 29, 2024
Product Development
Market reaction to Intellia data suggests perfection remains bar for gene editing
Clinical Report: Celldex advances in a second urticaria type, Eledon’s mAb helps Type I diabetes patients become insulin-independent, and more
BioCentury | May 10, 2024
Finance
Public equity report: iTeos, ADC Therapeutics, Eledon draw fundings
Biotechs all gave clinical updates during busy earnings week
BioCentury | Oct 24, 2023
Management Tracks
Viatris’ Malik to retire in April
Plus: New CFO for NewAmsterdam and more from Persephone, Eledon and Attgeno
Items per page:
1 - 4 of 4